Kirkwood Adams, MD
Cardiovascular Disease · Chapel Hill, NCNPI 1710069810
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,325 of the $28,586 with a category attached, or 74.6%. 11 manufacturers reported payments, led by Vifor Pharma, Inc. at 33.8% of the total. Reporting peaked in 2019 at $13,316 and has fallen 96.6% since, to $453 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $402.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$10K
- Amgen$10K
- Roche Diagnostics Corporation$6K
- Novartis$2K
- Eli Lilly$1K
- Novo Nordisk$263
- plus $626 from 5 others
Across 332 payments — averaging $14,636 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.3M
- Novartis$792K
- Livanova USA, Inc.$343K
- Boehringer Ingelheim$283K
- Astrazeneca UK Limited$255K
- Amgen$252K
- plus $625K from 8 others
What the payments were for
- Consulting fees$21,32575%
- Travel & lodging$3,95614%
- Food & beverage$3,25111%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 8 | $9,672 |
| Amgen | 13 | $9,599 |
| Roche Diagnostics Corporation | 7 | $5,553 |
| Novartis | 11 | $1,614 |
| Eli Lilly | 20 | $1,259 |
| Novo Nordisk | 3 | $263 |
| Astrazeneca UK Limited | 2 | $212 |
| Novartis Pharma AG | 2 | $187 |
| Delcath Systems | 1 | $135 |
| Merck | 3 | $77 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$9,537
- CD cobas Reagents$5,445
- ENTRESTO$997
- LEQVIO$251
- LCZ696D_ENTRESTO_CARDIOVASCULAR$145
- Hepzato Kit$135
How this compares
$28,586 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $8,665 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chapel Hill
- Timothy NicholsChapel Hill$113K
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Robert MentzDurham$489K
- Sean PokorneyMorganton$477K
- Adrian HernandezDurham$409K
- Sanjeev GulatiCharlotte$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.